Connecticut Statutes

§ 17b-491b — Reimbursement formula for drugs used to treat hemophilia A.

Connecticut § 17b-491b
JurisdictionConnecticut
Title 17bSocial Services
Ch. 319ffPrescription Drug Assistance

This text of Connecticut § 17b-491b (Reimbursement formula for drugs used to treat hemophilia A.) is published on Counsel Stack Legal Research, covering Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Conn. Gen. Stat. § 17b-491b (2026).

Text

The maximum allowable cost paid for antihemophilic Factor VII, VIII, IX and X products under the Medicaid program shall be the actual acquisition cost as reflected on the manufacturer's invoice plus eight per cent plus the professional dispensing fee established for covered outpatient drugs.

Free access — add to your briefcase to read the full text and ask questions with AI

Legislative History

(June Sp. Sess. P.A. 00-2, S. 35, 53; P.A. 04-76, S. 22; P.A. 11-44, S. 131; P.A. 13-234, S. 100; June Sp. Sess. P.A. 17-2, S. 200.) History: June Sp. Sess. P.A. 00-2 effective July 1, 2000; P.A. 04-76 deleted reference to “general assistance”; P.A. 11-44 deleted “state-administered general assistance”, effective July 1, 2011; P.A. 13-234 deleted reference to ConnPACE program, effective January 1, 2014; June Sp. Sess. P.A. 17-2 deleted provision re Factor VIII pharmaceuticals, added “antihemophilic Factor VII, VIII, IX and X products”, added reference to manufacturer's invoice re acquisition cost and added “plus the professional dispensing fee established for covered outpatient drugs”, effective October 31, 2017.

Nearby Sections

15
§ 17b-105e
Definitions.
View on official source ↗

Cite This Page — Counsel Stack

Bluebook (online)
Connecticut § 17b-491b, Counsel Stack Legal Research, https://law.counselstack.com/statute/ct/17b-491b.